Antibody therapy plus chemo for high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests adding the antibody dinutuximab-beta to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if this combination helps the immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age at diagnosis is between 1 and 30 years old.
- You have a confirmed diagnosis of high-risk neuroblastoma (your doctor will check specific tumor features).
- You have not had any cancer treatment before, or only had the first round of a specific chemotherapy plan.
- You have a tumor that can be seen on a scan (MRI, CT, MIBG, or PET) and is at least 1 cm in size.
- You are in generally good physical condition (able to do daily activities) with normal organ function (kidneys, liver, heart, lungs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
This study tests adding two medications (naxitamab and GM-CSF) to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma, a cancer of nerve cells. The goal is to help the body's immune system fight the cancer more effectively.
This study tests whether giving fewer chemotherapy drugs along with other targeted therapies (monoclonal antibodies) works well for children with high-risk neuroblastoma. It aims to reduce side effects while still treating the cancer effectively.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
Hear when a new High-Risk Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.